Recombinant Human IL29 protein

• Cat.No.: IL29-100H
• Product Overview: Recombinant Human IL29 protein was expressed in Escherichia coli.

Specification

• Description: IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.
• Source: E.coli
• Species: Human
• Form: Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4.
• Bio-activity: Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 10⁵ IU/mg.
• Molecular Mass: Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.
• Protein length: 181
• AA Sequence: GPVPTSKPTTTGKGCHIGRFKSLSP QELASFKKARDALEESLKLKNWSCS SPVFPGNWDLRLLQVRERPVALEAE LALTLKVLEAAAGPALEDVLDQPLH TLHHILSQLQACIQPQPTAGPRPRG RLHHWLHRLQEAPKKESAGCLEASV TFNLFRLLTRDLKYVADGNLCLRTS THPEST
• Endotoxin: Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method.
• Purity: >97% by SDS-PAGE and HPLC analysis.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.
• Tag: Non

Gene Information

• Gene Name: IL29
• Official Symbol: IL29
• Synonyms: IL29; interleukin 29 (interferon, lambda 1); interleukin 29; interleukin-29; IFNL1; IL 29; IFN-lambda-1; cytokine Zcyto21; interferon lambda-1; interferon-lambda-1; interferon, lambda 1; IL-29
• Gene ID: 282618
• mRNA Refseq: NM_172140
• Protein Refseq: NP_742152
• MIM: 607403
• UniProt ID: Q8IU54

Reviews

10/12/2022

Storage conditions are very simple and can be stored for a long time.

04/30/2022

Anti-pollution ability is very strong, not easy to be polluted.

09/12/2019

Labeling effect is very good, can be fluorescent labeling and so on.

Q&As

How should the dose of IL29 be determined?

The dose of IL29 should be determined according to the specific disease and patient situation, and the most appropriate dose usually needs to be determined through clinical trials and individualized treatment.

What is the difference between IL29 and IL28?

IL29 and IL28 are two similar interferons that are similar in structure and function, but with some minor differences such as receptor affinity and signaling pathways.

What are the advantages of IL29 compared with traditional drugs?

IL29 is highly targeted and safe, and can stimulate the response of the own immune system, which has better therapeutic effect and fewer side effects than traditional drugs.

Does IL29 have antioxidant effects?

At present, there are no clear studies to prove that IL29 has a direct antioxidant effect, but it may indirectly affect oxidative stress response by regulating immune system function.

Recombinant IL29 has potential in the treatment of which autoimmune diseases?

IL29 has potential in the treatment of rheumatoid arthritis, hepatitis B, psoriasis and other autoimmune diseases.

Are there side effects of IL29?

It may cause some mild side effects, such as fever, fatigue, headache, etc., but it is generally reversible, and serious side effects are rare.